Syed Z, Fahim A, Safdar M, Imtiaz R
Pak J Med Sci. 2024; 40(9):2036-2040.
PMID: 39416604
PMC: 11476162.
DOI: 10.12669/pjms.40.9.8739.
Yamada Y, Hamaji M, Okada H, Takahagi A, Ajimizu H, Koyasu S
Mediastinum. 2024; 8:43.
PMID: 39161585
PMC: 11330912.
DOI: 10.21037/med-23-70.
Dzialach L, Wojciechowska-Luzniak A, Maksymowicz M, Witek P
Front Endocrinol (Lausanne). 2024; 15:1399930.
PMID: 38948516
PMC: 11211248.
DOI: 10.3389/fendo.2024.1399930.
Cabezon-Gutierrez L, Pacheco-Barcia V, Carrasco-Valero F, Palka-Kotlowska M, Custodio-Cabello S, Khosravi-Shahi P
Mediastinum. 2024; 8:33.
PMID: 38881809
PMC: 11176988.
DOI: 10.21037/med-23-47.
Kim D, Lim Y, Kim S, Ock C, Youk J, Kim M
Thorac Cancer. 2023; 14(30):3001-3011.
PMID: 37675597
PMC: 10599973.
DOI: 10.1111/1759-7714.15089.
Risk factor analysis of thymoma resection and its value in guiding clinical treatment.
Du X, Cui J, Yu X, Yu L
Cancer Med. 2023; 12(12):13408-13414.
PMID: 37156630
PMC: 10315718.
DOI: 10.1002/cam4.6043.
Nomogram based on TNM stage to predict the prognosis of thymic epithelial tumors (TETs) patients undergoing extended thymectomy.
Li Y, Tang Z, Zhu X, Tian H
Front Surg. 2023; 10:1136166.
PMID: 36936648
PMC: 10020510.
DOI: 10.3389/fsurg.2023.1136166.
Immune checkpoints in thymic epithelial tumors: challenges and opportunities.
Girard N
Immunooncol Technol. 2022; 3:8-14.
PMID: 35757304
PMC: 9216246.
DOI: 10.1016/j.iotech.2019.09.002.
An overview: ongoing systemic therapy trials in thymic epithelial tumors around the world-will anything "hit"?.
Merveilleux du Vignaux C, Girard N
Mediastinum. 2022; 5:40.
PMID: 35118345
PMC: 8794377.
DOI: 10.21037/med-20-16.
The role of induction therapy for thymic malignancies: a narrative review.
Patel D, Shrager J, Padda S
Mediastinum. 2022; 4:36.
PMID: 35118304
PMC: 8794335.
DOI: 10.21037/med-20-20.
Treatment options for stage IVA thymic malignancies.
Girard N
Mediastinum. 2022; 3:39.
PMID: 35118265
PMC: 8794432.
DOI: 10.21037/med.2019.09.02.
Thymic malignancies: next-generation sequencing as a tool to select patients for targeted therapies and immunotherapies?.
Girard N
Mediastinum. 2022; 3:38.
PMID: 35118264
PMC: 8794339.
DOI: 10.21037/med.2019.09.03.
Induction chemotherapy for locally advanced thymic epithelial tumors: consideration from the RYTHMIC prospective cohort.
Nakagawa K
Mediastinum. 2022; 3:13.
PMID: 35118241
PMC: 8794291.
DOI: 10.21037/med.2019.04.03.
and as Major Microbiota in Thymic Epithelial Tumors.
Higuchi R, Goto T, Hirotsu Y, Otake S, Oyama T, Amemiya K
J Pers Med. 2021; 11(11).
PMID: 34834444
PMC: 8623653.
DOI: 10.3390/jpm11111092.
Future Perspective of Chemotherapy and Pharmacotherapy in Thymic Carcinoma.
Kitadai R, Okuma Y
Cancers (Basel). 2021; 13(20).
PMID: 34680386
PMC: 8533972.
DOI: 10.3390/cancers13205239.
Thymic tumours and their special features.
Basse C, Girard N
Eur Respir Rev. 2021; 30(162).
PMID: 34670805
PMC: 9488894.
DOI: 10.1183/16000617.0394-2020.
Genomic clustering analysis identifies molecular subtypes of thymic epithelial tumors independent of World Health Organization histologic type.
Padda S, Gokmen-Polar Y, Hellyer J, Badve S, Singh N, Vasista S
Oncotarget. 2021; 12(12):1178-1186.
PMID: 34136086
PMC: 8202771.
DOI: 10.18632/oncotarget.27978.
Radiotherapy for thymic epithelial tumours: a review.
Suveg K, Putora P, Joerger M, Iseli T, Fischer G, Ammann K
Transl Lung Cancer Res. 2021; 10(4):2088-2100.
PMID: 34012817
PMC: 8107733.
DOI: 10.21037/tlcr-20-458.
Immunotherapy vs platinum for advanced or metastatic thymic carcinoma: A protocol for systematic review and meta analysis.
Qian J, Tong Z, Zhang Y, Chen C
Medicine (Baltimore). 2021; 100(3):e23802.
PMID: 33545943
PMC: 7837854.
DOI: 10.1097/MD.0000000000023802.
A Rare Case of a High-Grade Thymic Squamous Cell Carcinoma Presenting as Cardiac Tamponade.
Rai M, Keogh A
Cureus. 2020; 12(7):e9366.
PMID: 32850235
PMC: 7445423.
DOI: 10.7759/cureus.9366.
